HDACs in multiple myeloma: potential benefits in maintenance phase
How is the landscape of Hodgkin lymphoma therapy changing?
Comparing continuous and fixed duration myeloma treatment with triplets and doublets
Comparison of native vs pegylated asparaginase for HR Ph chromosome-negative ALL
Biosimilars - the question of trials and approval